A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

NCT03366337 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

IgA Nephropathy
CKD Associated With Type 1 Diabetes
Focal Segmental Glomerulosclerosis
Autosomal Dominant Polycystic Kidney

Interventions

DRUG: Bardoxolone methyl capsules

Sponsor

Biogen